• 1
    Centers for Disease Control and Prevention. Viral hepatitis: statistics and surveillance. Accessed January 2010.
  • 2
    Lin SY, Chang ET, So SK. Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. HEPATOLOGY 2007; 46: 10341040.
  • 3
    Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep 2006; 121: 710719.
  • 4
    Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis — United States, 2007. MMWR Surveill Summ 2009; 58: 127.
  • 5
    Ward JW. Time for renewed commitment to viral hepatitis prevention. Am J Public Health 2008; 98: 779781.
  • 6
    Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994–2004. Clin Infect Dis 2008; 46: 18521858.
  • 7
    Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008; 168: 10991109.
  • 8
    IOM. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: National Academies Press; 2010.